Management of malignant dysgerminoma of the ovary

The evolution of treatment for malignant ovarian germ cell tumors has been one the most successful in history gynecologic oncology, with dysgerminoma as common type tumors. Since introduction platinum-based chemotherapy 1980s, 5-year survival rates early-stage dysgerminomas have close to 100%, and high 98% advanced stages. Despite this remarkable achievement, many questions remain routine treatment. By performing a literature review, we aim highlight both current unanswered modern management disease. These issues relate firstly surgical therapy, such role omentectomy lymphadenectomy, value complete resection, possibility fertility-sparing surgery. Second, question de-escalation early stages potential neoadjuvant will be addressed. Finally, brief overview developments new drug regimens given.